Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3420898 | 1.00 | CCR2 (0.84) | CCR2CYP2D6 | |
| SCHEMBL3425407 | 0.93 | CCR2 (0.86) | CCR2CYP2D6 | |
| SCHEMBL3426505 | 0.93 | CCR2 (0.89) | CCR2CYP2D6 | |
| SCHEMBL3426507 | 0.93 | CCR2 (0.89) | CCR2CYP2D6 | |
| SCHEMBL3425403 | 0.93 | CCR2 (0.86) | CCR2CYP2D6 | |
| SCHEMBL3425210 | 0.92 | CCR2 (1.00) | CCR2CYP2D6 | |
| SCHEMBL3425206 | 0.92 | CCR2 (1.00) | CCR2CYP2D6 | |
| SCHEMBL3425667 | 0.92 | CCR2 (1.00) | CCR2CYP2D6 | |
| SCHEMBL3423596 | 0.91 | CCR2 (1.00) | CCR2CYP2D6 | |
| SCHEMBL3423597 | 0.91 | CCR2 (1.00) | CCR2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108678-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | claimed |
| US-7291615-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | claimed |
| US-20040235836-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | claimed |
| US-7696205-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-20080108678-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-7291615-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-20040235836-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235836-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | CCR2 5/4885CYP2D6 3897/4885 |
| US-20080108678-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCL11, CCL2, CCR1 | CCR2 5/4885CYP2D6 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.